Enliven Therapeutics Quarterly Income Statement
NASDAQ: ELVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
40.98+0.35 (+0.86%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Enliven Therapeutics revenue and earnings
Enliven Therapeutics reported a net loss of $32.5 million, compared with a loss of $25.3 million a year earlier. Diluted earnings per share came in at -$0.49.
Summary generated from market data by MetaCap's automated system. Methodology
Enliven Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 37.21M | 27.82M | 34.28M | 25.10M | 28.58M | 31.69M | 26.90M | 27.07M | 24.60M | 25.99M | 22.73M | 24.25M |
| Research & Development | 29.00M | 20.69M | 21.25M | 18.23M | 21.49M | 24.89M | 20.72M | 21.26M | 18.83M | 19.97M | 17.91M | 19.61M |
| Operating Income | -37.21M | -27.82M | -34.28M | -25.10M | -28.58M | -31.69M | -26.90M | -27.07M | -24.60M | -25.99M | -22.73M | -24.25M |
| Other Income (Expense) | 4.72M | 4.20M | 4.62M | 4.95M | 3.25M | 3.15M | 3.72M | 3.91M | 4.65M | 3.25M | 3.36M | 3.48M |
| Income Tax | — | — | 0 | 0 | 0 | — | 0 | 0 | 232.00K | — | 0 | 0 |
| Net Income | -32.48M | -23.63M | -29.67M | -20.15M | -25.34M | -28.54M | -23.18M | -23.16M | -19.95M | -22.74M | -19.37M | -20.77M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.49 | -0.38 | -0.45 | -0.32 | -0.49 | -0.57 | -0.46 | -0.48 | -0.41 | -0.54 | -0.29 | -0.51 |
| EPS (Diluted) | -0.49 | -0.38 | -0.45 | -0.32 | -0.49 | -0.57 | -0.46 | -0.48 | -0.41 | -0.54 | -0.29 | -0.51 |
| Shares Outstanding (Basic) | 66.17M | 62.80M | — | 62.09M | 52.11M | 50.05M | — | 48.27M | 48.08M | 42.05M | — | 41.03M |
| Shares Outstanding (Diluted) | 66.17M | 62.80M | — | 62.09M | 52.11M | 50.05M | — | 48.27M | 48.08M | 42.05M | — | 41.03M |
| EBITDA | -37.20M | -27.81M | -34.20M | -25.03M | -28.50M | -31.62M | -26.83M | -26.99M | -24.52M | -25.91M | -22.65M | -24.17M |
This table shows 12 quarterly periods of Enliven Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 11 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow ELVN's reporting calendar. What is a income statement?